Why AbbVie Stock Remains a Strong Buy Option for Investors

Sunday, 5 May 2024, 17:44

Despite the patent cliff impact, AbbVie exhibits resilience and promises compelling growth prospects. The article highlights the incremental sales of innovative products like Skyrizi and Rinvoq that are offsetting Humira's decline. The company's stable dividend program and potential for future increases add to its appeal for income-seeking investors.
https://store.livarava.com/eac82575-0b07-11ef-a6c1-63e1980711b2.jpg
Why AbbVie Stock Remains a Strong Buy Option for Investors

Resilience Amid Patent Cliff Impact

Despite Humira's patent expiration hitting AbbVie (NYSE: ABBV), the company's sales decline has been less severe than anticipated, reflecting operational strength.

Growth from Innovative Products

  • Skyrizi: Rapidly growing psoriasis treatment with a market share of 35% in the U.S.
  • Rinvoq: Showing a significant year-over-year increase in sales and a promising growth trajectory.

Stable Dividend Program

AbbVie's consistent dividend growth over 52 years and a current yield of 3.8% make it an attractive choice for income-focused investors.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe